Dictionary: These measures have been retired as CDER has created new measures for FY13 which align to their four functional areas of 1) Regulatory Review and Drug Safety, 2) Drug Quality and Compliance, 3) Transparency and Public Outreach, and 4) Regulatory Science Research.
Percent of submissions reaching mid-cycle review during the month that required minimal or no additional data management prior to performing analyses and no requests for additional datasets were made to sponsor
Fiscal Year - 2012
Time
Target
Percent
Oct 2011
N/A
66
Nov 2011
N/A
82
Dec 2011
N/A
50
Jan 2012
N/A
TBD
Feb 2012
N/A
TBD
Mar 2012
N/A
TBD
Apr 2012
N/A
TBD
May 2012
N/A
TBD
Jun 2012
N/A
TBD
Jul 2012
N/A
TBD
Aug 2012
N/A
TBD
Sep 2012
N/A
TBD
Percent of submissions reaching mid-cycle review during the month that required additional data management prior to performing analyses, but no requests for additional datasets were made to the sponsor
Fiscal Year - 2012
Time
Target
Percent
Oct 2011
N/A
17
Nov 2011
N/A
9
Dec 2011
N/A
30
Jan 2012
N/A
TBD
Feb 2012
N/A
TBD
Mar 2012
N/A
TBD
Apr 2012
N/A
TBD
May 2012
N/A
TBD
Jun 2012
N/A
TBD
Jul 2012
N/A
TBD
Aug 2012
N/A
TBD
Sep 2012
N/A
TBD
Percent of submissions reaching mid-cycle review during the month that required additional data requests to sponsor for adequate analysis datasets
Note: The data provided on this website is produced on an ongoing basis for performance management purposes and is subject to change due to updates of preliminary estimates, corrections, or other reasons. In addition, FDA may change the type or amount of data provided on this website at any time. Information marked as "Completed" may include measures and/or key projects for which activities are ongoing but no longer tracked as part of FDA-TRACK.
